{"transactions":[{"id":4621370,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-17T20:28:41.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":488801,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000015","document":"form4-09172026_080936.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000015/form4-09172026_080936.xml","form_type":"4"}},{"id":4621369,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-17T20:28:41.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":18500,"price":37,"value":684500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000015","document":"form4-09172026_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000015/form4-09172026_080936.xml","form_type":"4"}},{"id":4621368,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-17T20:28:41.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000015","document":"form4-09172026_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000015/form4-09172026_080936.xml","form_type":"4"}},{"id":4467,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T20:15:08.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":507301,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000014","document":"form4-09042026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000014/form4-09042026_040901.xml","form_type":"4"}},{"id":4466,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-04T20:15:08.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":18500,"price":35.1158,"value":649642.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000014","document":"form4-09042026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000014/form4-09042026_040901.xml","form_type":"4"}},{"id":4465,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-04T20:15:08.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000014","document":"form4-09042026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000014/form4-09042026_040901.xml","form_type":"4"}},{"id":688777,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":46250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":525801,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":46250},"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688776,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":43.5947,"value":95908.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688775,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":10500,"price":42.8578,"value":450006.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":237444,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688774,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":32550,"price":42.0736,"value":1369495.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":247944,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688773,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":40.7762,"value":40776.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":280494,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688772,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":true,"shares":46250,"price":2.8968,"value":133977.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":281494,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688768,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":572051,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688767,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":88,"price":38.43,"value":3381.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688766,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":18412,"price":37.9311,"value":698387.4132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235332,"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688765,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688764,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":590551,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":688763,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":4281,"price":37.0868,"value":158768.5908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":688762,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":14219,"price":36.6396,"value":520978.4724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":239525,"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":688761,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":711584,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":43.5947,"value":95908.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":151994,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":711583,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":10500,"price":42.8578,"value":450006.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":154194,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":711582,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":32550,"price":42.0736,"value":1369495.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":164694,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":711581,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":40.7762,"value":40776.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":197244,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":727233,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-06-24T20:55:47.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":88,"price":38.43,"value":3381.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":198244,"source":{"system":"sec-edgar","filing":"0001859453-26-000008","document":"form4-06242026_080643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000008/form4-06242026_080643.xml","form_type":"4"}},{"id":727232,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-06-24T20:55:47.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":18412,"price":37.9311,"value":698387.4132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":198332,"source":{"system":"sec-edgar","filing":"0001859453-26-000008","document":"form4-06242026_080643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000008/form4-06242026_080643.xml","form_type":"4"}},{"id":780276,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-05-13T20:26:47.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":4281,"price":37.0868,"value":158768.5908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":216744,"source":{"system":"sec-edgar","filing":"0001859453-26-000007","document":"form4-05132026_080543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000007/form4-05132026_080543.xml","form_type":"4"}},{"id":780275,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-05-13T20:26:47.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":14219,"price":36.6396,"value":520978.4724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":221025,"source":{"system":"sec-edgar","filing":"0001859453-26-000007","document":"form4-05132026_080543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000007/form4-05132026_080543.xml","form_type":"4"}},{"id":807939,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-04-15T20:57:38.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":900,"price":45.5114,"value":40960.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended,"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $45.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000006","document":"form4-04152026_080434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/form4-04152026_080434.xml","form_type":"4"}},{"id":807938,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-04-15T20:57:38.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":7921,"price":44.5784,"value":353105.5064,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.20, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":236144,"source":{"system":"sec-edgar","filing":"0001859453-26-000006","document":"form4-04152026_080434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/form4-04152026_080434.xml","form_type":"4"}},{"id":807937,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-04-15T20:57:38.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":14130,"price":43.6649,"value":616985.037,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.24, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,032 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2026."}],"balance_after":244065,"source":{"system":"sec-edgar","filing":"0001859453-26-000006","document":"form4-04152026_080434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/form4-04152026_080434.xml","form_type":"4"}},{"id":881295,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-02-26T00:58:27.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":16925,"price":41.9839,"value":710577.5075,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":257163,"source":{"system":"sec-edgar","filing":"0001859453-26-000004","document":"form4-02262026_120224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000004/form4-02262026_120224.xml","form_type":"4"}},{"id":915648,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-07T01:00:15.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":137500,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":137500},"source":{"system":"sec-edgar","filing":"0001859453-26-000002","document":"form4-02062026_080211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000002/form4-02062026_080211.xml","form_type":"4"}},{"id":915647,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-02-07T01:00:15.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":68800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 623 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025."}],"balance_after":274088,"source":{"system":"sec-edgar","filing":"0001859453-26-000002","document":"form4-02062026_080211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000002/form4-02062026_080211.xml","form_type":"4"}},{"id":1240025,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-27T21:05:29.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":28.3183,"value":31150.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":204665,"source":{"system":"sec-edgar","filing":"0001415889-25-005841","document":"form4-02272025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925005841/form4-02272025_090225.xml","form_type":"4"}},{"id":1240024,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-27T21:05:29.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":7975,"price":27.5526,"value":219731.985,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":205765,"source":{"system":"sec-edgar","filing":"0001415889-25-005841","document":"form4-02272025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925005841/form4-02272025_090225.xml","form_type":"4"}},{"id":1240023,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-27T21:05:29.000Z","date":"2025-02-21","kind":"sale","planned":true,"acquired":false,"shares":10613,"price":27.8933,"value":296031.5929,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of three (3) business days, beginning on February 21, 2025 and ending on February 25, 2025."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"Pursuant to Rule 16a-3(g)(2) and (3)."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover tax withholding obligations associated with the vesting of RSUs pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.37 to $29.80, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":213740,"source":{"system":"sec-edgar","filing":"0001415889-25-005841","document":"form4-02272025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925005841/form4-02272025_090225.xml","form_type":"4"}},{"id":1254770,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:07:22.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":161500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":161500,"derivative":{"exercise_price":29.18,"expiration_date":"2035-02-17","underlying":"Class A Common Stock","underlying_shares":161500},"source":{"system":"sec-edgar","filing":"0001415889-25-004845","document":"form4-02202025_090218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925004845/form4-02202025_090218.xml","form_type":"4"}},{"id":1254769,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-20T21:07:22.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":80750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":224353,"source":{"system":"sec-edgar","filing":"0001415889-25-004845","document":"form4-02202025_090218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925004845/form4-02202025_090218.xml","form_type":"4"}},{"id":1304817,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":609051,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304816,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"exercise","planned":true,"acquired":false,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":610926,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":15625},"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304815,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":42,"value":78750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."}],"balance_after":143603,"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304814,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":145478,"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304813,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"sale","planned":true,"acquired":false,"shares":5650,"price":42.0334,"value":237488.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.19, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":143603,"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304812,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"exercise","planned":true,"acquired":true,"shares":5650,"price":2.8968,"value":16366.92,"ownership":{"direct":true},"balance_after":149253,"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304811,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"sale","planned":true,"acquired":false,"shares":9975,"price":41.5335,"value":414296.6625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.89 to $41.85, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":143603,"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1304810,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-01-10T21:06:50.000Z","date":"2025-01-08","kind":"exercise","planned":true,"acquired":true,"shares":9975,"price":2.8968,"value":28895.58,"ownership":{"direct":true},"balance_after":153578,"source":{"system":"sec-edgar","filing":"0001415889-25-001242","document":"form4-01102025_090146.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925001242/form4-01102025_090146.xml","form_type":"4"}},{"id":1323768,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-19","kind":"exercise","planned":true,"acquired":false,"shares":57661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":626551,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":57661},"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323767,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":684212,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323766,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":false,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":686087,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":15625},"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323765,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-19","kind":"exercise","planned":true,"acquired":true,"shares":57661,"price":2.8968,"value":167032.3848,"ownership":{"direct":true},"balance_after":143603,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323764,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":43.81,"value":82143.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323763,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":87817,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323762,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":4635,"price":44.0332,"value":204093.882,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.88 to $44.32, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323761,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":true,"shares":4635,"price":2.8968,"value":13426.668,"ownership":{"direct":true},"balance_after":90577,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323760,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":5023,"price":43.5217,"value":218609.4991,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.88 to $43.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323759,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":true,"shares":5023,"price":2.8968,"value":14550.6264,"ownership":{"direct":true},"balance_after":90965,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323758,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":2195,"price":42.3459,"value":92949.2505,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.74, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323757,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":true,"shares":2195,"price":2.8968,"value":6358.476,"ownership":{"direct":true},"balance_after":88137,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323756,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"sale","planned":true,"acquired":false,"shares":3772,"price":41.3264,"value":155883.1808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.87 to $41.82, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1323755,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-20T21:06:42.000Z","date":"2024-12-18","kind":"exercise","planned":true,"acquired":true,"shares":3772,"price":2.8968,"value":10926.7296,"ownership":{"direct":true},"balance_after":89714,"source":{"system":"sec-edgar","filing":"0001415889-24-029964","document":"form4-12202024_091238.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029964/form4-12202024_091238.xml","form_type":"4"}},{"id":1331847,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":701712,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331846,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":false,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":703587,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":15625},"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331845,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":100,"price":47.65,"value":4765.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331844,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":2.8968,"value":289.68,"ownership":{"direct":true},"balance_after":86042,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331843,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":1775,"price":46.9436,"value":83324.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.50 to $47.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331842,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":1775,"price":2.8968,"value":5141.82,"ownership":{"direct":true},"balance_after":87717,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331841,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":700,"price":47.5482,"value":33283.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.43 to $47.61, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331840,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":700,"price":2.8968,"value":2027.76,"ownership":{"direct":true},"balance_after":86642,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331839,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":14925,"price":46.9112,"value":700149.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.42 to $47.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1331838,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-12-13T21:07:45.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":14925,"price":2.8968,"value":43234.74,"ownership":{"direct":true},"balance_after":100867,"source":{"system":"sec-edgar","filing":"0001415889-24-029275","document":"form4-12132024_091242.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924029275/form4-12132024_091242.xml","form_type":"4"}},{"id":1348775,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":719212,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348774,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":721087,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348773,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":false,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":722962,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":15625},"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348772,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":49,"value":91875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348771,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":87817,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348770,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":48.76,"value":91425.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348769,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":87817,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348768,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":1381,"price":48.8042,"value":67398.6002,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.59 to $49.27, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348767,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":true,"shares":1381,"price":2.8968,"value":4000.4808,"ownership":{"direct":true},"balance_after":87323,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348766,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":7665,"price":48.1839,"value":369329.5935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.59 to $48.58, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348765,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":true,"shares":7665,"price":2.8968,"value":22203.972,"ownership":{"direct":true},"balance_after":93607,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348764,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":6579,"price":47.0485,"value":309532.0815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.59 to $47.55, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1348763,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-27T21:05:45.000Z","date":"2024-11-25","kind":"exercise","planned":true,"acquired":true,"shares":6579,"price":2.8968,"value":19058.0472,"ownership":{"direct":true},"balance_after":92521,"source":{"system":"sec-edgar","filing":"0001415889-24-027840","document":"form4-11272024_091139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924027840/form4-11272024_091139.xml","form_type":"4"}},{"id":1363105,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":738587,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363104,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":746087,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363103,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":747962,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363102,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":749837,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363101,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":751712,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363100,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":false,"shares":15625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter."}],"balance_after":753587,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":15625},"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363099,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":49,"value":367500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363098,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":7500,"price":2.8968,"value":21726.0,"ownership":{"direct":true},"balance_after":93442,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363097,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":49.4992,"value":92811.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363096,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":87817,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363095,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":49.5192,"value":92848.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363094,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":87817,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363093,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":1875,"price":49.5739,"value":92951.0625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.88, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363092,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":1875,"price":2.8968,"value":5431.5,"ownership":{"direct":true},"balance_after":87817,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363091,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":310,"price":50.351,"value":15608.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.13 to $50.78, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85942,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}},{"id":1363090,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2024-11-15T21:05:16.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":310,"price":2.8968,"value":898.008,"ownership":{"direct":true},"balance_after":86252,"source":{"system":"sec-edgar","filing":"0001415889-24-026944","document":"form4-11152024_091112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588924026944/form4-11152024_091112.xml","form_type":"4"}}],"next_cursor":"2024-11-15T21:05:16.000000Z,1363090"}